Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

2nd Next Generation Kinase Inhibitors Summit

Evvnt Promotion / evvnt
-
22.02.2023 - 23.02.2023  Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 am to 6:00 pm
 
Temi della conferenza
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
Scientific organizer
Hanson Wade
Annotazioni
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1446853-3?pid=4832
Mr. Min Ratcliffe
 
Categorie
Sanità Pubblica (Public Health), Servizi sanitari
Lingua
Inglese
Quote del Congresso
Free: USD 0.00
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Alumni Club Medizinische Universität WienAnästhesie in Entwicklungsländern e. V.Swiss Tropical and Public Health InstituteHelix - Forschung & Beratung WienAMREF - African Medical and Research FoundationEuropean Public Health Association (EUPHA)Charité International AcademyÖsterreichisches Rotes Kreuz